The all-American pharmaceutical company, Pfizer (NYSE:PFE), is looking to report its fourth-quarter and full year 2017 results next week and here are the things that you can expect from the company. Looking at the company’s previous quarter performance, they managed to hit positive figures with great dominating market performance.
Pfizer had a great 2017 run and a lot of analysts are expecting that the positive trend will continue with its coming fourth-quarter and whole year results. The company’s previous earnings were up by an incredible and surprising 3.08%; they also managed to stay ahead of most analysts’ expectations and forecasts from the same quarter.
Pfizer’s Previous Quarter
Looking at the overall growth of the company in the previous year, Pfizer managed to score a total of 18.7% growth for their shares. For the anticipated results, analysts are looking to pay close attention to their new products such as Xeljanz and Ibrance to contribute to their results; older products such as the Lyrica, Chantix, and Eliquis are also looking to contribute greatly.
One thing that may hinder the company’s 2017 performance is the reported supply shortage that they for their products from legacy Hospira portfolio. They announced that shortage on the same time their third-quarter results were unveiled. According to Pfizer, the supply shortages stemmed from the capacity constraints and technical issues.
All-in-all, the pharmaceutical company also raised their full-year adjusted earnings forecast by a total of 3 cents, putting the price range at $2.58 to $2.62 per share. They also updated their revenue forecast to $52.4 billion to $53.1 billion, from the latter $52 billion to $54 billion.
Future predictions and expectations for the company are as follows; analysts believe that Pfizer will update the commercialization plan for its upgraded oral SGLT-2 inhibitor.
Johnson & Johnson (NYSE:JNJ), Pfizer Deal
The pharmaceutical company is also currently arranging an acquisition deal for its consumer health business. According to sources that are familiar with the matter, the current race has depleted to two bidders after J&J pulled out, this leaves GlaxoSmithKline and Reckitt Benckiser on the acquisition deal. The bid will run until February 1, until then negotiations are still ongoing.
According to Johnson & Johnson’s Vice President of media relations Ernie Knewitz "While we would normally not comment on market speculation or rumors, in this instance we refute assertions that we are in negotiation for Pfizer's consumer business,"